These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31926324)

  • 21. Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience.
    Wong J; Fulp WJ; Strosberg JR; Kvols LK; Centeno BA; Hodul PJ
    Am J Surg; 2014 Nov; 208(5):775-780. PubMed ID: 24997491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.
    Birnbaum DJ; Turrini O; Vigano L; Russolillo N; Autret A; Moutardier V; Capussotti L; Le Treut YP; Delpero JR; Hardwigsen J
    Ann Surg Oncol; 2015 Mar; 22(3):1000-7. PubMed ID: 25190116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrinsic Contact Between T and N Classifications in Resected Well-Moderately Differentiated Locoregional Pancreatic Neuroendocrine Neoplasms.
    Xu JZ; Wang WQ; Zhang SR; Xu HX; Wu CT; Qi ZH; Gao HL; Ni QX; Liu L; Yu XJ
    Ann Surg Oncol; 2018 Mar; 25(3):647-654. PubMed ID: 29235006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of Lymph Node Metastasis in Resectable Well-differentiated Pancreatic Neuroendocrine Tumor.
    Harimoto N; Hoshino K; Muranushi R; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Araki K; Hosouchi Y; Suzuki H; Arakawa K; Hirai K; Fukazawa T; Ikota H; Shirabe K
    Pancreas; 2019 Aug; 48(7):943-947. PubMed ID: 31268980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours.
    Ricci C; Casadei R; Taffurelli G; Buscemi S; D'Ambra M; Monari F; Santini D; Campana D; Tomassetti P; Minni F
    Pancreatology; 2013; 13(6):589-93. PubMed ID: 24280574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can we predict recurrence in WHO G1-G2 pancreatic neuroendocrine neoplasms? Results from a multi-institutional Spanish study.
    Ausania F; Senra Del Rio P; Gomez-Bravo MA; Martin-Perez E; Pérez-Daga JA; Dorcaratto D; González-Nicolás T; Sanchez-Cabus S; Tardio-Baiges A
    Pancreatology; 2019 Mar; 19(2):367-371. PubMed ID: 30683515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multidisciplinary treatment strategy for advanced pancreatic neuroendocrine tumors- a single center experience.
    Tsuchikawa T; Hirano S; Tanaka E; Kato K; Matsumoto J; Sichinohe T
    Hepatogastroenterology; 2012; 59(120):2623-6. PubMed ID: 22497945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significance of lymph node metastasis in pancreatic neuroendocrine tumor.
    Taki K; Hashimoto D; Nakagawa S; Ozaki N; Tomiyasu S; Ohmuraya M; Arima K; Kaida T; Higashi T; Sakamoto K; Sakata K; Okabe H; Nitta H; Hayashi H; Chikamoto A; Beppu T; Takamori H; Hirota M; Baba H
    Surg Today; 2017 Sep; 47(9):1104-1110. PubMed ID: 28229300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.
    Boninsegna L; Panzuto F; Partelli S; Capelli P; Delle Fave G; Bettini R; Pederzoli P; Scarpa A; Falconi M
    Eur J Cancer; 2012 Jul; 48(11):1608-15. PubMed ID: 22129889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical significance of the preoperative main pancreatic duct dilation and neutrophil-to-lymphocyte ratio in pancreatic neuroendocrine tumors (PNETs) of the head after curative resection.
    Zhou B; Zhan C; Xiang J; Ding Y; Yan S
    BMC Endocr Disord; 2019 Nov; 19(1):123. PubMed ID: 31718651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study.
    Sallinen VJ; Le Large TYS; Tieftrunk E; Galeev S; Kovalenko Z; Haugvik SP; Antila A; Franklin O; Martinez-Moneo E; Robinson SM; Panzuto F; Regenet N; Muffatti F; Partelli S; Wiese D; Ruszniewski P; Dousset B; Edwin B; Bartsch DK; Sauvanet A; Falconi M; Ceyhan GO; Gaujoux S;
    HPB (Oxford); 2018 Mar; 20(3):251-259. PubMed ID: 28988702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of the 2010 WHO classification and a new prognostic proposal: A single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours.
    Ricci C; Casadei R; Taffurelli G; Campana D; Ambrosini V; Pagano N; Santini D; De Giorgio R; Ingaldi C; Tomassetti P; Zani E; Minni F
    Pancreatology; 2016; 16(3):403-10. PubMed ID: 26924664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the World Health Organization 2010 grading system in surgical outcome and prognosis of pancreatic neuroendocrine tumors.
    Yang M; Tian BL; Zhang Y; Su AP; Yue PJ; Xu S; Wang L
    Pancreas; 2014 Oct; 43(7):1003-8. PubMed ID: 24945681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET.
    Lombardi M; De Lio N; Funel N; Sardella C; Russo D; Urbani C; Rossi G; Campani D; Martino E; Marcocci C; Boggi U; Bogazzi F
    J Endocrinol Invest; 2015 Jun; 38(6):605-13. PubMed ID: 25501604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A rational approach to postoperative surveillance for resected non-functional pancreatic neuro-endocrine tumours.
    Feretis M; Wang T; Ghorani E; Balakrishnan A; Harper SJ; Jah A; Huguet EL; Praseedom RK; Liau SS
    Pancreatology; 2019 Oct; 19(7):1000-1007. PubMed ID: 31445889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Major postoperative complications after pancreatic resection for P-NETS are not associated to earlier recurrence.
    Valente R; Lykoudis P; Tamburrino D; Inama M; Passas I; Toumpanakis C; Luong TV; Davidson B; Imber C; Malagò M; Rahman SH; Shankar A; Sharma D; Caplin M; Fusai G
    Eur J Surg Oncol; 2017 Nov; 43(11):2119-2128. PubMed ID: 28821361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Tumor Markers for Predicting Disease-Free Survival in Surgically Resected Pancreatic Neuroendocrine Tumors.
    Zhou B; Fang B; Yan S; Wang W
    Clin Lab; 2017 Jul; 63(7):1251-1259. PubMed ID: 28792692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases.
    Ye L; Ye H; Zhou Q; Li Z; Lin Q; Tan L; Gao W; Fu Z; Zheng S; Chen R
    Int J Surg; 2016 May; 29():108-17. PubMed ID: 27000717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is the new classification of neuroendocrine pancreatic tumors of clinical help?
    Schindl M; Kaczirek K; Kaserer K; Niederle B
    World J Surg; 2000 Nov; 24(11):1312-8. PubMed ID: 11038199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence.
    Nanno Y; Toyama H; Otani K; Asari S; Goto T; Terai S; Ajiki T; Zen Y; Fukumoto T; Ku Y
    Pancreatology; 2016; 16(5):882-7. PubMed ID: 27350059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.